Thrombin Inhibitor 11 is a peptide-inspired scaffold designed to engage the active site and exosite regions of thrombin. Key residues mimic native substrate interactions while noncanonical features confer improved binding. Researchers quantify inhibition constants and map contact residues through structural methods. Applications include coagulation-enzyme mechanism studies and anticoagulant lead optimization.
Thrombin inhibitor 11 is a synthetic peptide compound designed to specifically modulate thrombin activity in biochemical and pharmacological research settings. As a targeted inhibitor, it interacts with thrombin, a serine protease central to the coagulation cascade, and is widely utilized in studies focused on blood clotting mechanisms, hemostasis, and related signal transduction pathways. The structural attributes and selectivity of Thrombin inhibitor 11 make it a valuable tool for dissecting the molecular underpinnings of thrombin-mediated processes, supporting both fundamental and applied research in biochemistry, hematology, and vascular biology.
Enzyme inhibition studies: Thrombin inhibitor 11 is extensively employed in research exploring the functional role of thrombin in coagulation and fibrinolysis. By providing a potent and selective means to block thrombin activity, it enables precise characterization of downstream substrates and cofactors involved in clot formation. Researchers leverage this peptide to delineate the kinetics, substrate specificity, and regulatory mechanisms of thrombin, facilitating the development of novel anticoagulant strategies and enhancing understanding of protease-driven signaling events.
Signal transduction research: The compound serves as a crucial reagent in studies investigating thrombin-mediated cellular signaling. Thrombin activates a variety of cell surface receptors, notably protease-activated receptors (PARs), which are implicated in vascular function, inflammation, and tissue remodeling. By using Thrombin inhibitor 11 to selectively inhibit thrombin, scientists can dissect the contribution of specific signaling pathways to cellular responses such as platelet aggregation, endothelial activation, and leukocyte recruitment, thereby elucidating the broader physiological and pathological roles of thrombin signaling.
Peptide-based assay development: The well-defined inhibitory profile of Thrombin inhibitor 11 supports its application in the development and optimization of in vitro assays for thrombin detection and activity measurement. Laboratories utilize this peptide to establish robust negative controls and to validate assay specificity, ensuring reliable quantification of thrombin activity in complex biological samples. Its consistent performance enhances the reproducibility and interpretability of biochemical assays used in both academic and industrial research environments.
Protein-protein interaction studies: Thrombin inhibitor 11 is also valuable in mapping the interactions between thrombin and its natural substrates or inhibitors. Through competitive binding experiments and structural analyses, researchers can use this peptide to investigate the binding interfaces and conformational dynamics of thrombin complexes. Such studies inform the rational design of next-generation thrombin inhibitors and contribute to a deeper mechanistic understanding of protease-inhibitor interactions at the molecular level.
Anticoagulation mechanism exploration: In experimental models of coagulation, Thrombin inhibitor 11 enables the controlled modulation of thrombin activity to study the consequences of selective inhibition on clot formation, stability, and dissolution. This targeted approach allows for the assessment of compensatory pathways, feedback regulation, and the interplay between coagulation factors under defined conditions. The insights gained from these investigations inform the broader field of hemostasis research and support the identification of novel intervention points within the coagulation cascade.
1. TMEM16F and dynamins control expansive plasma membrane reservoirs
3. The spatiotemporal control of signalling and trafficking of the GLP-1R
4. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More